Refill company profile: what is public, what is not

As of June 2026, Refill's public site does not disclose who owns the company, leadership names, outside funding, headquarters location, or how many clinics use the platform. It also does not name every 503A partner pharmacy in the network or publish aggregate order volumes. Where a fact is not in Refill's public materials, it is undisclosed rather than estimated here.

This is common for privately held B2B platforms and is not, by itself, a red flag. But it does mean due diligence comes from direct requests: contracting entity, partner pharmacy identities, references, and contract terms. The absence of public corporate detail shifts where you get answers, not whether you should ask.

Request corporate facts in the sales conversation: which legal entity you are contracting with, who stands behind the platform, and how long it has operated. Ask for the specific 503A partner pharmacies your clinic would route to and proof of LegitScript certification and state licensure — the platform's legitimacy rests on its partners. Ask for references from clinics like yours, full fee schedule including software fees at your projected volume, and read cancellation terms before signing.

On parts you can verify yourself, confirm refill.co describes telehealth infrastructure — pharmacy network, provider coverage, Refill Connect — with published platform tiers. For comparison, Fizy Health publishes pass-through per-vial 503A pricing before checkout, a disclosed facilitation fee, and LegitScript-certified partners — the kind of pricing visibility to weigh alongside corporate transparency.